PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28776488-1 2017 Amino-functionalized mesoporous silica nanoparticles (MSN-NH2) were synthesized by a post-grafting method and further studied as carriers for doxorubicin hydrochloride (DOX) delivery. Doxorubicin 142-167 moesin Homo sapiens 54-57 28776488-1 2017 Amino-functionalized mesoporous silica nanoparticles (MSN-NH2) were synthesized by a post-grafting method and further studied as carriers for doxorubicin hydrochloride (DOX) delivery. Doxorubicin 169-172 moesin Homo sapiens 54-57 28776488-2 2017 The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials. Doxorubicin 55-58 moesin Homo sapiens 66-69 28776488-2 2017 The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials. Doxorubicin 55-58 moesin Homo sapiens 66-69 28776488-2 2017 The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials. Doxorubicin 75-78 moesin Homo sapiens 66-69 28776488-2 2017 The morphology, structure, and property of MSN-NH2 and DOX-loaded MSN-NH2 (DOX@MSN-NH2) were studied using various techniques, such as transmission electron microscopy, Fourier transformed infrared spectroscopy, N2 adsorption-desorption isotherms, and zeta potentials. Doxorubicin 75-78 moesin Homo sapiens 66-69 28776488-4 2017 The results indicated that the loading content of DOX increased with the decrease of MSN-NH2/DOX mass ratio and/or the increase of amino density. Doxorubicin 50-53 moesin Homo sapiens 85-88 28776488-5 2017 DOX@MSN-NH2 exhibited a pH-dependent drug release, drug release increased as the pH value decreased. Doxorubicin 0-3 moesin Homo sapiens 4-7 28776488-6 2017 Compared with MSN-NH2, which were neglectable cytotoxicity against non-small-cell lung cancer (A549) cells, DOX@MSN-NH2 displayed remarkable cytotoxicity toward A549 cells in dose- and time-dependent manners. Doxorubicin 108-111 moesin Homo sapiens 112-115 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 33-44 moesin Homo sapiens 84-87 28933253-10 2017 Interestingly, Moesin silencing restored the 1001 sensitivity to Doxorubicin. Doxorubicin 65-76 moesin Homo sapiens 15-21 28849842-7 2017 Furthermore, photoinitiated polymerization cross-linked methacrylated hyaluronic acid (m-HA) gel was covered on the surface of DOX@MSN to improve its tumour targeting ability. Doxorubicin 127-130 moesin Homo sapiens 131-134 28849842-9 2017 Importantly, subsequent US treatment could not only trigger SDT of MSN but also promote DOX release from MSN to show chemotherapeutic activity. Doxorubicin 88-91 moesin Homo sapiens 105-108 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 33-44 moesin Homo sapiens 193-196 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 46-49 moesin Homo sapiens 84-87 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 46-49 moesin Homo sapiens 193-196 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 176-179 moesin Homo sapiens 84-87 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 176-179 moesin Homo sapiens 193-196 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 176-179 moesin Homo sapiens 84-87 28363599-4 2017 Upon loading the antitumor drug, doxorubicin (DOX), into the mesoporous channels of MSN nanoparticles, CDHA with a diameter size of 3nm completely blocked the pore entrance of DOX-encapsulated MSN nanoparticles with a pore size of about 3nm, thus preventing the premature leakage of DOX and increasing the antitumor activity until being triggered by specific stimuli in the tumor environment. Doxorubicin 176-179 moesin Homo sapiens 193-196 28363599-5 2017 The results of the cell imaging and cytotoxicity studies demonstrated that the redox/enzyme dual-responsive DOX-encapsulated MSN-SS-CDHA nanoparticles can selectively deliver and control the release of DOX into tumor cells. Doxorubicin 108-111 moesin Homo sapiens 125-128 28363599-5 2017 The results of the cell imaging and cytotoxicity studies demonstrated that the redox/enzyme dual-responsive DOX-encapsulated MSN-SS-CDHA nanoparticles can selectively deliver and control the release of DOX into tumor cells. Doxorubicin 202-205 moesin Homo sapiens 125-128 28363599-6 2017 Ex vivo fluorescence images showed a much stronger fluorescence of MSN-SS-CDHA-DOX in the tumor site than in normal tissues, greatly facilitating the accumulation of DOX in the target tissue. Doxorubicin 79-82 moesin Homo sapiens 67-70 28407530-7 2017 Apoptosis analysis confirmed that DOX and p53 could be co-delivered to the Hela cells by MSN-SS-CP nanocarriers and induced significant cell apoptosis. Doxorubicin 34-37 moesin Homo sapiens 89-92 28686414-1 2017 In this paper, mesoporous silica nanoparticle (MSN) loaded with doxorubicin (DOX) and capped with tumor-homing/-penetrating peptide tLyP-1-modified tungsten disulfide quantum dots (WS2-HP) was designed and applied as a stimuli-responsive "Cluster Bomb" for high-performance tumor suppression. Doxorubicin 64-75 moesin Homo sapiens 47-50 28686414-1 2017 In this paper, mesoporous silica nanoparticle (MSN) loaded with doxorubicin (DOX) and capped with tumor-homing/-penetrating peptide tLyP-1-modified tungsten disulfide quantum dots (WS2-HP) was designed and applied as a stimuli-responsive "Cluster Bomb" for high-performance tumor suppression. Doxorubicin 77-80 moesin Homo sapiens 47-50 28174081-6 2017 And from which DOX@MSN-NH-N=C-PAD10 is chosen as the most satisfactory one for the further in vitro cytotoxicity studies and cellular uptake studies. Doxorubicin 15-18 moesin Homo sapiens 19-22 28174081-7 2017 The results demonstrate that DOX@MSN-NH-N=C-PAD10 with an excellent pH-sensitivity can enter HeLa cells to release DOX intracellular due to the weakly acidic pH intracellular and kill the cells. Doxorubicin 29-32 moesin Homo sapiens 33-36 28174081-7 2017 The results demonstrate that DOX@MSN-NH-N=C-PAD10 with an excellent pH-sensitivity can enter HeLa cells to release DOX intracellular due to the weakly acidic pH intracellular and kill the cells. Doxorubicin 115-118 moesin Homo sapiens 33-36 27191965-3 2016 In this work, we developed folate (FA) receptor targeted magnetic-mesoporous silica nanoparticles for the codelivery of VEGF shRNA and doxorubicin (DOX) (denoted as M-MSN(DOX)/PEI-FA/VEGF shRNA). Doxorubicin 135-146 moesin Homo sapiens 167-170 27346782-3 2016 The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60). Doxorubicin 15-40 moesin Homo sapiens 219-222 27346782-3 2016 The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60). Doxorubicin 15-40 moesin Homo sapiens 224-231 27346782-3 2016 The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60). Doxorubicin 42-45 moesin Homo sapiens 219-222 27346782-3 2016 The release of doxorubicin hydrochloride (DOX) could be triggered under a mild acidic environment (lysosome, pH = 5.0) due to the protonation of C60-TEG-COO-, which induced the dissociation of the C60-TEG-COOH modified MSN (MSN@C60). Doxorubicin 42-45 moesin Homo sapiens 224-231 27191965-4 2016 Our data showed that M-MSN(DOX)/PEI-FA could strongly condense VEGF shRNA at weight ratios of 30:1, and possesses higher stability against DNase I digestion and sodium heparin. Doxorubicin 27-30 moesin Homo sapiens 23-26 27191965-6 2016 The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX). Doxorubicin 34-37 moesin Homo sapiens 110-113 27191965-6 2016 The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX). Doxorubicin 114-117 moesin Homo sapiens 110-113 27191965-6 2016 The intracellular accumulation of DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN(DOX)/PEI-FA were more easily taken up than nontargeted M-MSN(DOX). Doxorubicin 114-117 moesin Homo sapiens 110-113 27016140-4 2016 The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers. Doxorubicin 17-28 moesin Homo sapiens 118-128 27016140-4 2016 The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers. Doxorubicin 17-28 moesin Homo sapiens 118-121 26945977-7 2016 Additionally, HHG2C18-L became more positive at tumor intracellular pH and enhanced Coulombic repulsion with MSN-NH2, leading to increased sequential staggered release of erlotinib and DOX. Doxorubicin 185-188 moesin Homo sapiens 109-112 27016140-4 2016 The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers. Doxorubicin 30-33 moesin Homo sapiens 118-128 27016140-4 2016 The second drug, doxorubicin (DOX, 32wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3(+), affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers. Doxorubicin 30-33 moesin Homo sapiens 118-121 23997043-5 2014 To achieve targeting therapy, an anticancer drug, doxorubicin (Dox), was loaded into MSN@Alg, and a arginine, glycine, and aspartic acid (RGD)-based peptide was functionalized onto the surface of MSN@Alg for the purpose of specific targeting. Doxorubicin 63-66 moesin Homo sapiens 85-88 26878288-1 2016 In this study, dual functionalized mesoporous silica nanoparticle (Dual-MSN) with functions of carboxyl modification and chirality was successfully developed and its special contribution in delivering doxorubicin hydrochloride (DOX) in vitro was mainly studied. Doxorubicin 201-226 moesin Homo sapiens 72-75 26878288-1 2016 In this study, dual functionalized mesoporous silica nanoparticle (Dual-MSN) with functions of carboxyl modification and chirality was successfully developed and its special contribution in delivering doxorubicin hydrochloride (DOX) in vitro was mainly studied. Doxorubicin 228-231 moesin Homo sapiens 72-75 26878288-2 2016 Characteristics of Dual-MSN and its application as DOX carrier were intensively explored by comparing with naked non-functionalized MSN (Naked MSN). Doxorubicin 51-54 moesin Homo sapiens 24-27 26878288-3 2016 The results indicated that both Naked MSN and Dual-MSN significantly controlled DOX release due to the release hindrance caused by mesopores. Doxorubicin 80-83 moesin Homo sapiens 38-41 26878288-3 2016 The results indicated that both Naked MSN and Dual-MSN significantly controlled DOX release due to the release hindrance caused by mesopores. Doxorubicin 80-83 moesin Homo sapiens 51-54 26878288-5 2016 DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei. Doxorubicin 0-3 moesin Homo sapiens 17-20 26878288-5 2016 DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei. Doxorubicin 0-3 moesin Homo sapiens 41-44 26878288-5 2016 DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei. Doxorubicin 25-28 moesin Homo sapiens 41-44 26878288-5 2016 DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei. Doxorubicin 25-28 moesin Homo sapiens 41-44 26878288-5 2016 DOX loaded Naked MSN and DOX loaded Dual-MSN presented better cytotoxicity than DOX due to carrier-mediated endocytosis and the favorable intercalation of DOX into DNA in the nuclei. Doxorubicin 25-28 moesin Homo sapiens 41-44 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 20-23 moesin Homo sapiens 36-39 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 36-39 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 36-39 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 36-39 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 26878288-6 2016 The cytotoxicity of DOX loaded Dual-MSN was better than DOX loaded Naked MSN owing to its enhanced cellular uptake induced by chirality of Dual-MSN, demonstrating that double functions of Dual-MSN had unique advantages in improving antitumor effect of DOX towards MCF-7 cells and thus confirming its special contribution in DOX delivery. Doxorubicin 56-59 moesin Homo sapiens 73-76 32263193-7 2016 The application potential of the PDA-MSN hybrid nanocarriers is demonstrated by an unprecedentedly high drug (DOX) loading capacity of 1000 mg g-1, a sustained drug release, as well as enhanced killing efficiency of cancer cells at low dosage. Doxorubicin 110-113 moesin Homo sapiens 37-40 26690044-5 2016 Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX). Doxorubicin 72-75 moesin Homo sapiens 68-71 26690044-5 2016 Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX). Doxorubicin 72-75 moesin Homo sapiens 301-304 26690044-5 2016 Results demonstrated that EpCAM conjugation increased binding of Ap-MSN-DOX to EpCAM over-expressing SW620 colon cancer cells but not EpCAM-negative Ramos cells, resulting in enhanced cellular uptake and increased cytotoxicity of the DOX in SW620 cells when compared to non-Ap-modified nanoparticles (MSN-DOX). Doxorubicin 234-237 moesin Homo sapiens 68-71 26690044-6 2016 Additionally, Ap-MSN-DOX exhibited significant inhibition effects on the expression of EpCAM on SW620 cells. Doxorubicin 21-24 moesin Homo sapiens 17-20 25620848-10 2014 In vivo tumor-growth inhibition experiments with BALB/c nude mice demonstrated a highly efficient tumor-growth inhibition rate of DOX-loaded LbL-MSNs, suggesting that the novel type of LbL-MSN materials hold great potentials in anticancer drug delivery. Doxorubicin 130-133 moesin Homo sapiens 145-148 32261575-3 2014 The results show that the CytC capped nanocarriers have excellent doxorubicin (DOX) loading efficiency (414 mug mg-1 MSN) and the leakage of the drug is only 16% at pH 7.4 phosphate-buffered saline for 72 h. Simultaneously, the DOX release percentage can reach 54% by decreasing the pH to 5.5. Doxorubicin 79-82 moesin Homo sapiens 117-120 24940057-4 2014 For targeting therapy, the anticancer drug doxorubicin was loaded into MSN@Alg microspheres, and the (lysine)4-tyrosine-arginine-glycine-aspartic acid (K4YRGD) peptide was functionalized onto the surface of MSN@Alg for targeting liver cancer cells, hepatocellular carcinoma (HepG2). Doxorubicin 43-54 moesin Homo sapiens 71-74 24940057-4 2014 For targeting therapy, the anticancer drug doxorubicin was loaded into MSN@Alg microspheres, and the (lysine)4-tyrosine-arginine-glycine-aspartic acid (K4YRGD) peptide was functionalized onto the surface of MSN@Alg for targeting liver cancer cells, hepatocellular carcinoma (HepG2). Doxorubicin 43-54 moesin Homo sapiens 207-210 24940057-6 2014 In addition, the intracellular drug delivery efficiency was greatly enhanced (ie, 3.5-fold) for the arginine-glycine-aspartic acid (RGD)-labeled, doxorubicin-loaded MSN@Alg drug delivery system compared with the non-RGD case. Doxorubicin 146-157 moesin Homo sapiens 165-168 24392791-5 2014 Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions. Doxorubicin 105-108 moesin Homo sapiens 90-93 24392791-5 2014 Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions. Doxorubicin 122-125 moesin Homo sapiens 90-93 24392791-5 2014 Unique changes in gene expressions and gene ontology terms, which were caused only by the MSN-based DDS (DOX-loaded MSNs, DOX@MSNs) but not by free drug doxorubicin (DOX) and/or the carrier MSNs, were discovered and proposed to be responsible for the varied cell death mechanisms, including the greatly enhanced necrosis due to amplified oxidative stress and the apoptosis related with DNA/RNA synthesis and cell cycle inhibitions. Doxorubicin 122-125 moesin Homo sapiens 90-93 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 0-11 moesin Homo sapiens 64-67 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 0-11 moesin Homo sapiens 79-82 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 13-16 moesin Homo sapiens 64-67 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 13-16 moesin Homo sapiens 79-82 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 53-56 moesin Homo sapiens 64-67 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 53-56 moesin Homo sapiens 79-82 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 53-56 moesin Homo sapiens 64-67 32262716-6 2015 Doxorubicin (DOX), as a model drug, was used to form DOX-loaded MSN@AgNPs (DOX@MSN@AgNPs) and then to assess the drug release behaviors from the DA-responsive delivery system. Doxorubicin 53-56 moesin Homo sapiens 79-82 25985912-7 2015 The DOX-loaded MSN-SS-HA was more cytotoxic against HCT-116 cells than NIH-3T3 (CD44 receptor-negative) cells due to the enhanced cellular uptake of MSN-SS-HA. Doxorubicin 4-7 moesin Homo sapiens 15-18 26505004-3 2015 The as-synthesized HMSN-PEG nanoparticles exhibited higher loading capacity of anticancer drug (Doxorubicin) and better sustained release property than MSN and MSN-PEG particles. Doxorubicin 96-107 moesin Homo sapiens 20-23 26505004-6 2015 Furthermore, the DOX-loaded HMSN-PEG nanoparticles exhibited higher cytotoxicity than the DOX-loaded MSN and MSN-PEG nanoparticles against Hep-G2 cells. Doxorubicin 17-20 moesin Homo sapiens 29-32 26505004-6 2015 Furthermore, the DOX-loaded HMSN-PEG nanoparticles exhibited higher cytotoxicity than the DOX-loaded MSN and MSN-PEG nanoparticles against Hep-G2 cells. Doxorubicin 90-93 moesin Homo sapiens 101-104 24980623-7 2014 The M-MSN were loaded with anticancer drug Doxorubicin and the efficacy of the DOX loaded M-MSN was evaluated through in vitro cytotoxicity, fluorescence microscopy, and apoptosis studies. Doxorubicin 79-82 moesin Homo sapiens 6-9 24980623-7 2014 The M-MSN were loaded with anticancer drug Doxorubicin and the efficacy of the DOX loaded M-MSN was evaluated through in vitro cytotoxicity, fluorescence microscopy, and apoptosis studies. Doxorubicin 79-82 moesin Homo sapiens 92-95 23997043-5 2014 To achieve targeting therapy, an anticancer drug, doxorubicin (Dox), was loaded into MSN@Alg, and a arginine, glycine, and aspartic acid (RGD)-based peptide was functionalized onto the surface of MSN@Alg for the purpose of specific targeting. Doxorubicin 50-61 moesin Homo sapiens 85-88 23997043-6 2014 The results showed that the intracellular drug delivery efficiency was greatly enhanced (i.e., 3.5-folds) for the Dox/MSN@Alg-RGD drug delivery system. Doxorubicin 114-117 moesin Homo sapiens 118-121 32261387-6 2014 In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity. Doxorubicin 79-82 moesin Homo sapiens 98-101 32261387-6 2014 In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity. Doxorubicin 79-82 moesin Homo sapiens 115-118 32261387-6 2014 In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity. Doxorubicin 103-106 moesin Homo sapiens 98-101 32261387-6 2014 In vitro studies using a nasopharyngeal carcinoma cell line (HNE-1) prove that DOX loaded PAA-ACL-MSN (DOX@PAA-ACL-MSN) is endocytosed and demonstrates efficient operation at lysosomal pH, leading to significant cytotoxicity. Doxorubicin 103-106 moesin Homo sapiens 115-118 32046364-4 2020 The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX). Doxorubicin 235-246 moesin Homo sapiens 30-33 24073830-7 2013 After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately. Doxorubicin 50-53 moesin Homo sapiens 82-85 24073830-7 2013 After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately. Doxorubicin 50-53 moesin Homo sapiens 99-102 24073830-7 2013 After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately. Doxorubicin 71-74 moesin Homo sapiens 82-85 24073830-7 2013 After being in the slightly acidic condition, the DOX release from the DOX-loaded MSN@Gelatin (DOX/MSN@Gelatin) occurred immediately. Doxorubicin 71-74 moesin Homo sapiens 99-102 23543911-6 2013 The in vitro cell culture experiments showed that not only PNiPAM/AA@SiO2 particles were more biocompatible and lower cytotoxic than MSN, but also DOX@PNiPAM/AA@SiO2 had higher drug releasing efficiency in the lysosomes and stronger inhibitory effect on tumor cell growth than DOX@MSN. Doxorubicin 147-150 moesin Homo sapiens 281-284 22019849-4 2011 The in vitro release profiles of DOX from the MSN-based prodrug systems showed a strong dependence on the environmental pH values. Doxorubicin 33-36 moesin Homo sapiens 46-49 35388835-2 2022 Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA). Doxorubicin 61-72 moesin Homo sapiens 33-36 35388835-2 2022 Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA). Doxorubicin 61-72 moesin Homo sapiens 108-111 35388835-2 2022 Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA). Doxorubicin 61-72 moesin Homo sapiens 231-234 35388835-2 2022 Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA). Doxorubicin 74-77 moesin Homo sapiens 108-111 35388835-2 2022 Mesoporous silica nanoparticles (MSN-COOH) were prepared and doxorubicin (DOX) was loaded into the pores of MSN-COOH, and then polyethyleneimine (PEI) and anisamide (AA) were modified on the surface of mesoporous silica, named DOX@MSN-PEI-AA(DMPA). Doxorubicin 74-77 moesin Homo sapiens 231-234 32553643-7 2020 DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment. Doxorubicin 0-3 moesin Homo sapiens 4-7 32553643-7 2020 DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment. Doxorubicin 75-78 moesin Homo sapiens 4-7 32553643-7 2020 DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment. Doxorubicin 75-78 moesin Homo sapiens 4-7 32553643-7 2020 DOX-MSN-SS-CH-FA showed superior tumor suppressing activity as compared to DOX-MSN or DOX alone in the treatment of Ehrlich Ascites Carcinoma (EAC) induced breast cancer with significantly reduced hematological and organ specific toxicities associated with DOX treatment. Doxorubicin 75-78 moesin Homo sapiens 4-7 32329202-8 2020 In vitro cytotoxicity assay indicates that DOX loaded mixture nanoparticles (ratio of PLL-MSN to PLG-MSN is 1:1) can be triggered for drug release in HeLa cells, resulting in 88% of cell killing. Doxorubicin 43-46 moesin Homo sapiens 90-93 32329202-8 2020 In vitro cytotoxicity assay indicates that DOX loaded mixture nanoparticles (ratio of PLL-MSN to PLG-MSN is 1:1) can be triggered for drug release in HeLa cells, resulting in 88% of cell killing. Doxorubicin 43-46 moesin Homo sapiens 101-104 32263329-3 2013 Here, we report hybrid mesoporous nanoparticles of PEGylated silica-poly[2-(dimethylamino)ethyl acrylate] (PEGylated MSN-g-PDMAEA) that can deliver and release the anti-cancer drug doxorubicin (DOX) to tumor cells in a pH dependent switch on/off status. Doxorubicin 181-192 moesin Homo sapiens 117-120 32263329-3 2013 Here, we report hybrid mesoporous nanoparticles of PEGylated silica-poly[2-(dimethylamino)ethyl acrylate] (PEGylated MSN-g-PDMAEA) that can deliver and release the anti-cancer drug doxorubicin (DOX) to tumor cells in a pH dependent switch on/off status. Doxorubicin 194-197 moesin Homo sapiens 117-120 23711784-4 2013 The functionalization with carboxyl caused the pore surface of the nanocarrier more negative than native MSN, which could provide attractive forces between the nanoparticles and positively charged doxorubicin hydrochloride (DOX). Doxorubicin 197-222 moesin Homo sapiens 105-108 23711784-4 2013 The functionalization with carboxyl caused the pore surface of the nanocarrier more negative than native MSN, which could provide attractive forces between the nanoparticles and positively charged doxorubicin hydrochloride (DOX). Doxorubicin 224-227 moesin Homo sapiens 105-108 32261203-5 2013 The results showed that DOX-loaded MSNs were successfully incorporated into composite nanofibers with different MSN (or DOX) contents. Doxorubicin 24-27 moesin Homo sapiens 35-38 32261203-5 2013 The results showed that DOX-loaded MSNs were successfully incorporated into composite nanofibers with different MSN (or DOX) contents. Doxorubicin 120-123 moesin Homo sapiens 35-38 32261203-6 2013 Among them, the PLLA/1.0% DOX@10% MSN nanofibers exhibited good particle distribution and improved thermal stability. Doxorubicin 26-29 moesin Homo sapiens 34-37 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 26-51 moesin Homo sapiens 74-77 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 26-51 moesin Homo sapiens 88-91 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 53-56 moesin Homo sapiens 74-77 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 53-56 moesin Homo sapiens 88-91 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 63-66 moesin Homo sapiens 74-77 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 63-66 moesin Homo sapiens 88-91 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 63-66 moesin Homo sapiens 74-77 23598077-3 2013 The cumulative release of doxorubicin hydrochloride (DOX) from DOX-loaded MSN-PLGA (DOX@MSN-PLGA) was pH-dependent and the release rate was much higher at pH 5.5 than that at pH 7.4. Doxorubicin 63-66 moesin Homo sapiens 88-91 23598077-4 2013 The cytotoxicity results indicated that the blank MSN-PLGA was biocompatible and the DOX@MSN-PLGA had potent in vitro cytotoxicity effect similar to free DOX. Doxorubicin 85-88 moesin Homo sapiens 50-53 23598077-4 2013 The cytotoxicity results indicated that the blank MSN-PLGA was biocompatible and the DOX@MSN-PLGA had potent in vitro cytotoxicity effect similar to free DOX. Doxorubicin 85-88 moesin Homo sapiens 89-92 35388835-3 2022 DMPA specifically entered tumor cells through AA-mediated receptor endocytosis; PEI dissociated from the surface of the MSN in the acidic environment of cellular lysosomes/endosomes due to protonation of PEI, resulting in steady release of the encapsulated DOX from the pores of MSN in the cytoplasm of the target cells. Doxorubicin 257-260 moesin Homo sapiens 120-123 35151045-2 2022 The MNBA grafted nanoparticle MSN-SS-MNBA shows excellent blocking performance with negligible leakage when loaded with doxorubicin (DOX), and the release profiles illustrate stimuli-responsive property when triggered by GSH. Doxorubicin 120-131 moesin Homo sapiens 30-33 35151045-2 2022 The MNBA grafted nanoparticle MSN-SS-MNBA shows excellent blocking performance with negligible leakage when loaded with doxorubicin (DOX), and the release profiles illustrate stimuli-responsive property when triggered by GSH. Doxorubicin 133-136 moesin Homo sapiens 30-33 32223128-3 2020 Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell. Doxorubicin 55-66 moesin Homo sapiens 38-41 32223128-3 2020 Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell. Doxorubicin 68-71 moesin Homo sapiens 38-41 32290047-12 2020 The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. Doxorubicin 230-241 moesin Homo sapiens 205-208 32046364-4 2020 The optimal formulation of an MSN with polyethylene glycol (2% and 5%) and chitosan was undertaken, to produce sterically stabilized, hydrophilic MSNs, capable of efficient loading and delivery of the hydrophobic anti-neoplastic drug, doxorubicin (DOX). Doxorubicin 248-251 moesin Homo sapiens 30-33 32046364-7 2020 The 2% pegylated MSN formulation (PCMSN) had the highest DOX loading capacity (0.98 mgdox/mgmsn), and a sustained release profile over 72 h. Pegylated-drug nanoconjugates were effective at a concentration range between 20-50 mug/mL, inducing apoptosis in cancer cells, and affirming their potential as effective drug delivery vehicles. Doxorubicin 57-60 moesin Homo sapiens 17-20 31872318-2 2019 We herein construct an efficient cell-targeting drug delivery system (Sgc8-MSN/Dox) based on aptamer-modified mesoporous silica nanoparticles that relies on the tumor-targeting ability of the aptamer Sgc8 to deliver doxorubicin (Dox) to leukemia cells in a targeted way, thereby improving therapeutic efficacy and reducing toxicity. Doxorubicin 216-227 moesin Homo sapiens 75-78 31872318-2 2019 We herein construct an efficient cell-targeting drug delivery system (Sgc8-MSN/Dox) based on aptamer-modified mesoporous silica nanoparticles that relies on the tumor-targeting ability of the aptamer Sgc8 to deliver doxorubicin (Dox) to leukemia cells in a targeted way, thereby improving therapeutic efficacy and reducing toxicity. Doxorubicin 229-232 moesin Homo sapiens 75-78 31872318-3 2019 In this work, Sgc8-MSN/Dox showed sustained Dox release, and they targeted and efficiently killed CCRF-CEM human acute T lymphocyte leukemia cells, suggesting potential as a cancer therapy. Doxorubicin 23-26 moesin Homo sapiens 19-22 31872318-3 2019 In this work, Sgc8-MSN/Dox showed sustained Dox release, and they targeted and efficiently killed CCRF-CEM human acute T lymphocyte leukemia cells, suggesting potential as a cancer therapy. Doxorubicin 44-47 moesin Homo sapiens 19-22 31377647-4 2019 The model drug doxorubicin (Dox) was efficiently loaded within the channels of MSN-hyd-MOP (encapsulation efficiency about 87%). Doxorubicin 15-26 moesin Homo sapiens 79-82 31377647-4 2019 The model drug doxorubicin (Dox) was efficiently loaded within the channels of MSN-hyd-MOP (encapsulation efficiency about 87%). Doxorubicin 28-31 moesin Homo sapiens 79-82 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 48-51 moesin Homo sapiens 59-62 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 48-51 moesin Homo sapiens 72-75 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 84-87 moesin Homo sapiens 59-62 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 84-87 moesin Homo sapiens 72-75 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 84-87 moesin Homo sapiens 59-62 31377647-5 2019 The increased acidity in endo-/lysosome promote Dox-loaded MSN-hyd-MOP (MSN-hyd-MOP@Dox) release Dox quickly. Doxorubicin 84-87 moesin Homo sapiens 72-75 30102469-7 2018 Importantly, the synergistic photothermal therapy-chemotherapy of the RGD-Bi2 S3 @MSN/DOX significantly ablates the highly malignant OS. Doxorubicin 86-89 moesin Homo sapiens 82-85 30959408-6 2019 Both in vitro and in vivo studies proved that LM@MSN/DOX@HA could significantly inhibit solid tumor growth under near infrared (NIR) irradiation by synergistic photothermal/chemotherapy. Doxorubicin 53-56 moesin Homo sapiens 49-52 30572156-4 2019 In vitro cell experiments demonstrated that the as-prepared nanovehicles (denoted as DOX/MSN@CaCO3@CM) could be efficiently uptaken by LNCaP-AI prostate cancer cells and even exhibited a better anti-tumor efficiency than free DOX. Doxorubicin 226-229 moesin Homo sapiens 89-92 30572156-5 2019 In addition, Live/Dead cell detection and apoptosis experiment demonstrated that MSN/DOX@CaCO3@CM could effectively induce apoptosis-related death in prostate cancer cells. Doxorubicin 85-88 moesin Homo sapiens 81-84 31336697-6 2019 MSN@PDA loaded with doxorubicin (hydrophilic) and fingolimod (hydrophobic) was studied via a systematic in vitro approach (cellular internalization, intracellular drug distribution and cytotoxicity). Doxorubicin 20-31 moesin Homo sapiens 0-3 31336697-8 2019 Drug-loaded, copolymer-coated MSN@PDA showed effective cellular uptake, intracellular release and an amplified cytotoxic effect with both doxorubicin and fingolimod. Doxorubicin 138-149 moesin Homo sapiens 30-33 31114189-4 2019 Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH). Doxorubicin 6-17 moesin Homo sapiens 58-61 31114189-4 2019 Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH). Doxorubicin 6-9 moesin Homo sapiens 58-61 31114189-4 2019 Then, Doxorubicin (Dox) was encapsulated into the pore of MSNs, followed by capping with tumor-targeting molecules hyaluronic acid (HA) through electrostatic interactions to form the final product consist of Dox loaded, TPP attached, HA capped mesoporous silica nanoparticles (MSN-DPH). Doxorubicin 19-22 moesin Homo sapiens 58-61 30660963-2 2019 Imine bonds acted as the pH-cleavable linker between copolymer gatekeepers and MSN to promote the controlled-release performance of DOX. Doxorubicin 132-135 moesin Homo sapiens 79-82 30660963-3 2019 The DOX-loaded nanoparticles (Polymer@MSN-DOX) were spherical with a diameter of approximately 150 nm. Doxorubicin 4-7 moesin Homo sapiens 38-41 30660963-3 2019 The DOX-loaded nanoparticles (Polymer@MSN-DOX) were spherical with a diameter of approximately 150 nm. Doxorubicin 42-45 moesin Homo sapiens 38-41 30660963-5 2019 Confocal microscopy studies and in vitro cytotoxicity results revealed that Polymer@MSN-DOX could smoothly enter HepG2 cells to release DOX and show a high cytotoxicity. Doxorubicin 88-91 moesin Homo sapiens 84-87 30572156-6 2019 In vivo antitumor results demonstrated that DOX/MSN@CaCO3@CM administration could remarkably suppress the tumor growth. Doxorubicin 44-47 moesin Homo sapiens 48-51 30606519-5 2019 In addition, the rGO/MSN/PDA showed pH-response DOX release abilities, which means higher release of DOX in tumor cells. Doxorubicin 48-51 moesin Homo sapiens 21-24 30606519-5 2019 In addition, the rGO/MSN/PDA showed pH-response DOX release abilities, which means higher release of DOX in tumor cells. Doxorubicin 101-104 moesin Homo sapiens 21-24 30539634-5 2019 We loaded doxorubicin (DOX) as anticancer biomolecule into the pores of MSN and capped with COP. Doxorubicin 10-21 moesin Homo sapiens 72-75 30539634-5 2019 We loaded doxorubicin (DOX) as anticancer biomolecule into the pores of MSN and capped with COP. Doxorubicin 23-26 moesin Homo sapiens 72-75 30102469-9 2018 Hence, the smart RGD-Bi2 S3 @MSN/DOX theranostic platform is a promising candidate for future applications in CT monitoring and synergistic treatment of malignant tumors. Doxorubicin 33-36 moesin Homo sapiens 29-32 29595852-3 2018 Herein, we fabricated doxorubicin hydrochloride (DOX)- and indocyanine green (ICG)-loaded microneedle (MN) patches (PVP@DOX/MSN@ICG) using a two-step casting process. Doxorubicin 22-47 moesin Homo sapiens 124-127 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 48-59 moesin Homo sapiens 40-43 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 48-59 moesin Homo sapiens 70-73 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 48-59 moesin Homo sapiens 70-73 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 78-81 moesin Homo sapiens 40-43 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 78-81 moesin Homo sapiens 70-73 29392452-11 2018 Our results suggest that EphA2-targeted MSN for doxorubicin delivery (MSN-YSA-DOX) are more effective than MSN-DOX in treating breast cancer cell lines in vitro. Doxorubicin 78-81 moesin Homo sapiens 70-73 28917803-6 2018 Gate DNA were modified to the surface of the mesoporous silica (MSN) by electrostatic attraction to encapsulate DOX. Doxorubicin 112-115 moesin Homo sapiens 64-67 29146540-2 2018 Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX. Doxorubicin 188-191 moesin Homo sapiens 62-70 29146540-2 2018 Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX. Doxorubicin 188-191 moesin Homo sapiens 179-187 29146540-3 2018 Upon the stimulus of ROS, ROSP@MSN@DOX shows good release performance at physiological conditions. Doxorubicin 35-38 moesin Homo sapiens 26-34 29146540-5 2018 Furthermore, after treated with ROSP@MSN@DOX at a concentration of 100 mug/mL for 24 h, the viability of Hela cells is reduced to 40.5%; Control experiments demonstrate that, when Hela cells are pretreated with active oxygen scavenger, cell viability is about 65.3% due to the significant decrease of intracellular reactive oxygen species. Doxorubicin 41-44 moesin Homo sapiens 32-40 28917803-7 2018 After the above-mentioned RCA process, its result that long DNA chain containing a base fragment complementary to gate DNA, would be hybridized to the gate DNA strand on the surface of MSN, which opened the MSN hole and released the drug DOX into cell for HeLa cell therapy. Doxorubicin 238-241 moesin Homo sapiens 185-188 28917803-7 2018 After the above-mentioned RCA process, its result that long DNA chain containing a base fragment complementary to gate DNA, would be hybridized to the gate DNA strand on the surface of MSN, which opened the MSN hole and released the drug DOX into cell for HeLa cell therapy. Doxorubicin 238-241 moesin Homo sapiens 207-210 28888000-5 2017 Stimulus-induced release of the DOX was studied in the different pH and GSH, which showed the embedded DOX can be controlled release from MSN channels. Doxorubicin 32-35 moesin Homo sapiens 138-141 28958879-8 2017 Of note, a transwell chamber assay demonstrated that the migration and invasion of tumour cells were markedly inhibited by ADH-1-HA-MSN/DOX. Doxorubicin 136-139 moesin Homo sapiens 132-135 28958879-9 2017 Furthermore, Western blotting analysis revealed that ADH-1-HA-MSN/DOX inhibited tumour cell invasion and metastasis by down-regulating N-cadherin expression. Doxorubicin 66-69 moesin Homo sapiens 62-65 28888000-5 2017 Stimulus-induced release of the DOX was studied in the different pH and GSH, which showed the embedded DOX can be controlled release from MSN channels. Doxorubicin 103-106 moesin Homo sapiens 138-141